Abstract
Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor defined by the presence of histological features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Its prevalence ranges from 1%-5% of all primary liver cancers. We report the case of a 55-year-old cirrhotic male patient admitted to our university hospital for dysphagia, revealing a 10 cm lower-third esophageal metastasis of an unresectable cHCC-ICC with stemcell features. Computed tomography and abdominal magnetic resonance imaging scans revealed multiple hepatic lesions combining features of both HCC and ICC, associated with synchronous bone metastasis. Histological and immunohistochemical analyses of biopsies from the esophageal lesion and the hepatic tumor confirmed the diagnosis of cHCC-ICC with a stem cell-subtype, according to the World Health
INTRODUCTION
Primary liver cancer is the sixth most common cancer worldwide [1] . The majority of intrahepatic cancers are hepatocellular carcinomas (HCCs) or intrahepatic cholangiocarcinomas (ICCs). The prevalence of hepato cholangiocarcinoma (cHCCICC), combining histological features of HCC and ICC, ranges from 1% to 5% of primary hepatic cancers [2] . In 1949, Allen and Lisa [3] were the first to describe and classify cHCCICC into three subtypes (A, B and C). The classification subse quently evolved until the latest World Health Organization classification, proposed in 2010 (Table 1 ) [4] . Here we report the case of a patient diagnosed with a cHCCICC of stem cellsubtype, presenting with dysphagia and revealing an esophageal metastasis.
CASE REPORT
A 55yearold male was admitted to the University Hospital of Nantes, France, in January 2017 for inves tigation of a recent and elective dysphagia to solids associated with an alteration in general status (ECOG score 2) and weight loss of 14 kg.
The patient had a medical history of schizophrenia, alcoholic cirrhosis with ChildPugh score A and a daily alcohol intake of 30 g, Barrett's esophagus C1M6, and heavy cigarette smoking.
The first biological analyses showed isolated thrombocytopenia of 107 G/L, and normal renal and hepatic functions. The Creactive protein level was 9.9 mg/L.
Esophageal endoscopy ( Figure 1 ) revealed a sig nificant, quasiobstructive lesion of the lower third of the esophagus. Histological analysis confirmed an esophageal localization of an undifferentiated carcinoma, with immunohistochemical analysis indicating HCC with positive hepatocyte antigen.
Thoracoabdominopelvic computed tomography (CT) and abdominal magnetic resonance imaging (MRI) scans were performed. CT scans were performed before and after injection of contrast media, including arterial, portal and delayed phase at 5 min. MRI scan included T1weighted sequence with fat suppression before and after injection of gadolinium chelates at the same phases. CT and MRI scan analyses ( Figure  2 ) revealed the esophageal lesion and multiple hepatic nodules, mainly located in the right liver. Hepatic tumors exhibited atypical imaging features for classic HCC but showed combined imaging features of both HCC with peripheral arterial enhancement and delayed wash out, and ICC with delayed central fibrous enhan cement. The tumors more closely resembled ICC. Metastases were present in adrenal glands (33 mm on the right adrenal gland and 17 mm on the left adrenal gland) and lymph nodes of the celiac region, associated with a bony lesion of the right iliac branch invading the pubic symphysis.
All tumor markers were normal: alpha fetoprotein (αFP): 1.8 ng/mL (normal range: 0.88.8 ng/mL); carbohydrate antigen 199 (CA199): 4.5 U/mL (normal range: < 37 U/mL); and, carcinoembryonic antigen: 2.4 µg/L (normal range: < 5 µg/L).
A liver biopsy was performed. Histological and immunohistochemical analyses showed cHCCICC with stem cell features (small cells) and an intermediate cell subtype, as described in Table 1 . The tumor consisted Upper digestive endoscopy showed a 10-cm polypoid tumor at 30 cm from incisors.
of small cuboidal cells arranged in a ductal pattern at the borders of nodules, in continuity with a trabe cular pattern at the center. Tumor cells concomitantly expressed hepatocyte antigen HepPar1 and cytokeratin 19, normally expressed by biliary cells (Figure 3) . The tumor cells appeared to be growing within and replacing regenerative nodules of cirrhosis.
The patient was treated with systemic intravenous gemcitabine and cisplatin combined chemotherapy (gemcitabine 1000 mg/m 2 and cisplatin 25 mg/m² every week for 2 wk, with 1 wk of rest before a new cycle). He received two cycles of chemotherapy. During the followup, the patient showed a progressive altera tion in general condition, with an ECOG score of 3, associated with the appearance of diffuse bone pain. A bone scintigraphy was performed 2 mo after the beginning of chemotherapy, and revealed a multifocal metastatic spread over the entire axial and peripheral skeleton with right iliopubic and voluminous right humeral lesions. The patient was then managed with 
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when considering the major features of HCC (arterial phase hyperenhancement, wash out and capsule appearance) [17, 18] . However, the addition of nonHCC features in the radiologic assessment could improve the diagnostic accuracy [18] . Histological diagnosis is the gold standard, but is difficult to obtain in the absence of surgical specimens. The conduct of liver biopsies to sample both components of cHCCICC is infrequent. In a series of 23 resected cHCCICC, all of the tumors were misdiagnosed at preoperative histology, with 20 considered to be HCC and three classed as ICC [19] . As in the case presented here, criteria for identifying cHCCICC have been proposed previously [20] . The combination of elevated serum tumor markers and enhancement patterns on imaging should strongly suggest the diagnosis of cHCCICC in the following circumstances: imaging features of both ICC and HCC, regardless of marker levels; elevation of both αFP and CA199, regardless of imaging appearance; or discordance between imaging and tumor marker elevation (typical HCC enhancement pattern with elevated CA199 or typical ICC enhancement pattern with elevated αFP) [20] . The combination of histological, radiological and biological criteria is important to identify cHCCICC patients. Even in patients with cirrhosis and liver tumor with typical enhancement patterns of HCC, biopsies should be advocated in the presence of biological or imaging features suggesting a cHCCICC, as the best supportive care and died 87 d after the beginning of treatment.
DISCUSSION
To our knowledge, this is the first report of an esophageal metastasis of a cHCCICC. Esophageal metastases are uncommon. In HCC, the incidence of metastatic esophageal tumors is low, accounting for less than 0.4% [5] . Few case reports have described the presence of esophageal metastases from HCC or ICC [614] . These metastases could develop by the spread of tumor cells infiltrating the portal system [15] . The dissemination by hepatofugal portal flow to the esophagus seems to be one possible route for esophageal metastasis [8] . There are no current guidelines for the treatment of unresectable, locally advanced or metastatic cHCC ICC. We recently described the first series of patients with unresectable cHCCICC treated with gemcitabine plus platinumbased chemotherapy. In that retrospective study, including 30 patients, according to RECIST criteria, the partial response rate was 28.6%, stable disease rate 50% and progressive disease rate 21.4%. Median progressionfree survival and overall survival were 9.0 mo and 16.2 mo, respectively [16] . The diagnosis of cHCCICC is challenging. The ra diological diagnosis is difficult due to the high frequ ency of cHCCICC mimicking HCC, from 30% to 50% prognosis and the management of these tumors could be different [21] .
ARTICLE HIGHLIGHTS

Case characteristics
A 55-year-old cirrhotic male patient was admitted for dysphagia.
Clinical diagnosis
Elective dysphagia for solids associated with an alteration in general status and a weight loss of 14 kg.
Differential diagnosis
Primary esophageal cancer.
Laboratory diagnosis
Normal renal and hepatic functions. Normal carbohydrate antigen 19-9, carcinoembryonic antigen and alpha fetoprotein.
Imaging diagnosis
Thoraco-abdomino-pelvic computed tomography and abdominal magnetic resonance imaging scans were performed and revealed hepatic lesions combining imaging features of both hepatocellular carcinoma, and intrahepatic cholangiocarcinoma.
Pathological diagnosis
Stem cell-subtype hepatocholangiocarcinoma.
Treatment
Chemotherapy: gemcitabine -cisplatin.
Term explanation
Hepatocholangiocarcinoma is a primary hepatic tumor representing less than 5% of all hepatic tumors. This is the first report of an esophageal metastasis of a hepatocholangiocarcinoma.
Experiences and lessons
The diagnosis of hepatocholangiocarcinoma is challenging. The addition of non-HCC features in the radiologic assessment could improve the diagnostic accuracy.
